Email Us
Call Us
AUSTIN, Texas – August 10, 2021 – A preclinical study performed by Altogen Labs has demonstrated functional delivery of small RNA and plasmid DNA across the blood-brain barrier into glioblastoma tissue, a result announced publicly in July 2021 and one of the more difficult delivery problems in neuro-oncology drug development.
The blood-brain barrier remains the principal obstacle to treating primary brain tumors. Compounds that perform well in vitro frequently fail in vivo simply because they never reach the tumor. Altogen Labs scientists designed and executed the in vivo work behind this announcement, developing and modifying the transfection protocol required to achieve efficient delivery into glioblastoma tissue in both spontaneous and chemically induced murine glioma syngeneic models.
The study demonstrated functional cargo delivery of negatively charged biomolecules — chemically modified siRNA and a 3.7 kb plasmid DNA construct — through the blood-brain barrier, together with high reproducibility across animals. Reproducibility is the metric that distinguishes a usable preclinical delivery platform from an isolated observation, and it is the standard Altogen Labs applies to every validated model in its portfolio.
This work reflects a capability set that few independent CROs can offer end to end: study design, model selection, formulation and encapsulation, in vivo dosing across multiple administration routes, and downstream molecular confirmation by qRT-PCR, automated Western blot, and ELISA. Sponsors pursuing gene therapy, oligonucleotide therapeutics, and CNS-targeted programs can access the full sequence from a single laboratory.
Altogen Labs offers glioblastoma and brain cancer research in subcutaneous, orthotopic, and luciferase-tagged configurations, including U87, U87-Luc, U251, U118, A172, LN229, SF268, SF295, SF539, SNB-19, SNB-75, and SK-N-AS models, alongside its broader validated collection.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research services and biology CRO services worldwide. The company maintains an extensive portfolio of in-house validated xenograft models — CDX, PDX, syngeneic, organoids, and NAMs — and extensive experience in efficacy xenograft studies and safety toxicology studies for IND applications and regulatory submissions.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com
Source: Newswire, “Altogen Biosystems Announced Its In Vivo Nanoparticle-Based Transfection Reagent Is Effective in Brain-Targeted Drug Delivery and Capable of Overcoming Blood-Brain Barrier,” July 19, 2021.